Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ixmyelocel-T

Phase 3Cell therapy

VVericel Corporation

Ixmyelocel-T is one of 111 biologic programs targeting Osteonecrosis. It is currently in Phase 3.

4

Indications

7

Total Trials

0

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

IschemiaActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

Dilated CardiomyopathyActive, not recruiting

OsteonecrosisPhase 3

Active, not recruiting

IschemiaPhase 3

Active, not recruiting

Peripheral Arterial DiseasePhase 2

Active, not recruiting

Dilated CardiomyopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Ischemia

#DrugCompanyPhaseTrials

Adenocard

Isordil

Osmitrol

BB. Braun Medical Inc.

Cardizem

BBausch Health Americas, Inc.

Flagyl

DDePuy Orthopaedics

Garamycin

SSchering-Plough

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Avlosulfon

AAlmirall, S.A.

Remodulin

United Therapeutics

Circadin

NNeurim Pharmaceuticals Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy3 trials

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Completed·VVericel Corporation·Phase 2·NCT01670981·114 enrolled

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Completed·VVericel Corporation·Phase 2·NCT01020968·22 enrolled

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Completed·VVericel Corporation·Phase 2·NCT00765518·40 enrolled

Ischemia1 trial

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Completed·VVericel Corporation·Phase 3·NCT01483898·41 enrolled

Peripheral Arterial Disease1 trial

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Completed·VVericel Corporation·Phase 2·NCT00468000·86 enrolled

Osteonecrosis1 trial

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Completed·VVericel Corporation·Phase 3·NCT00505219·11 enrolled

Cell Therapy1 trial

Cell Therapy for Craniofacial Bone Defects

Completed·UUniversity of Michigan·Phase 1/2·NCT01616953·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ixmyelocel-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ixmyelocel-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ixmyelocel-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vericel Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: VVericel Corporation

Related News